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Abstract
Introduction: Mitochondrial dysfunction plays a central
role  in  the  general  pathogenesis  of  non-alcoholic 
fatty  liver  disease  (NaflD),  increasing  the  risk  of 
developing  steatosis  and  subsequent  hepatocellular 
inflammation. We aimed to assess hepatic mitochondr-
ial function by a non-invasive  13C-methionine breath
test  (MeBT)  in  patients  with  histologically  proven
NaflD. 
Methods: 118 NaflD-patients and 18 healthy controls
were examined by MeBT. liver biopsy specimens were
evaluated according to the NasH scoring system. 
Results: Higher grades of NasH activity and fibrosis
were  independently  associated  with  a  significant  de-
crease  in  cumulative  13C-exhalation  (expressed  as
cPDR(%)). cPDR1.5h was markedly declined in patients
with NasH and NasH cirrhosis compared to patients
with  simple  steatosis  or  borderline  diagnosis
(cPDR1.5h: 3.24 ﾱ 1.12% and 1.32 ﾱ 0.94% vs. 6.36 ﾱ
0.56% and 4.80 ﾱ 0.88% respectively; p<0.001). 13C-
exhalation  further  declined  in  the  presence  of  ad-
vanced fibrosis which was correlated with NasH ac-
tivity (r = 0.36). The area under the RoC curve (au-
RoC) for NasH diagnosis was estimated to be 0.87 in
the total cohort and 0.83 in patients with no or mild
fibrosis (f0-1). 
Conclusion: The  13C-methionine breath test indicates
mitochondrial dysfunction in non-alcoholic fatty liver
disease and predicts higher stages of disease activity. It
may, therefore, be a valuable diagnostic addition for
longitudinal  monitoring  of  hepatic  (mitochondrial)
function in non-alcoholic fatty liver disease.
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INTRoDuCTIoN
Non-alcoholic fatty liver disease (NaflD) is currently
the most common liver disease in the developed world
and has been recognized as a leading cause of crypto-
genic liver cirrhosis.
The  pathogenesis  of  NaflD  has  been  tightly
linked to insulin resistance (IR) and the metabolic syn-
drome,  although  the  progression  from  steatosis  to
steatohepatitis (NasH) is not well understood [1-3]. 
accumulating evidence indicates that mitochondri-
al dysfunction plays a central role in the pathogenesis
of NaflD both for steatosis development and sub-
sequent hepatocellular inflammation, raising the pos-
sibility  that  NaflD  is  a  mitochondrial  disease  [4].
accordingly, morphologic changes in liver mitochon-
dria and evidence of oxidative stress have been ob-
served  in  patients  and  animal  models  with  NasH.
These mitochondrial abnormalities include depletion
of mitochondrial (mtDNa), decreased activity of res-
piratory  chain  complexes  and  impaired  ʲ-oxidation
[5-9]. 
While  decreased  oxidation  of  fatty  acids  favours
the development of steatosis, respiratory chain dys-
function can directly lead to the production of reac-
tive oxygen species (Ros), resulting in lipid peroxida-
tion and initiation of mitochondrial apoptotic path-
ways. 
liver biopsy may be essential for primary diagnosis
of NasH as it represents the only diagnostic proce-
dure  that  can  distinguish  (benign)  steatosis  from
steatohepatitis,  and  allows  accurate  evaluation  of  fi-
brosis, but due to its invasive character it is ineligible
for frequent monitoring of disease progression or sur-
veillance of treatment interventions. 
The 13C-methionine breath test (MeBT) is a non-in-
vasive diagnostic instrument for in vivo assessment of
hepatic mitochondrial function. Methionine is an im-
portant donor of methyl groups and mainly metabo-
lized by hepatic transmethylation, resulting in the pro-
duction of a carbon fragment at the oxidation level of
formaldehyde  which  can  be  finally  converted  into
Co2. a key enzyme of this metabolic pathway, the sar-
cosine  oxidase  complex,  seems  to  be  present  exclu-
sively in the mitochondria. Therefore the proportion
of  13Co2 produced from orally administered methyl-
13C labelled methionine could serve as an indicator of
hepatic mitochondrial oxidation capacity. 
In recent clinical trials, the MeBT has been used to
explore mitochondriotoxic effects of alcohol, drug in-
duced steatohepatitis and, in particular, chronic HIv-
infection [10-12]. although the proportion of exhalat-
ed  13Co2 is rather small (6-8%) even in healthy sub-
jects, we could clearly separate conditions of hepatic
mitochondrial  stress  with  an  excellent  inter-  and  in-
traindividual reproducibility [13-15]. More recently, we
have demonstrated significant improvement of hepat-
ic mitochondrial function in a patient with non-alco-
holic  steatohepatitis  and  metabolic  syndrome  after
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[16].
other breath test substrates, such as methacetin or
caffeine  which  are  metabolised  by  microsomal  cy-
tochrome P450 enzymes, have been used for monitor-
ing general hepatic function in NaflD. These studies
have  demonstrated  decreased  microsomal  activity  in
patients with NasH and advanced fibrosis. However,
a substrate metabolised by mitochondrial decarboxyla-
tion might be more sensitive and, in particular, specific
for detecting mitochondrial dysfunction in early pre-fi-
brotic  stages  of  NasH  [17,  18].  The  present  study
was, therefore, aimed (i) to investigate hepatic mito-
chondrial  function  by  MeBT  in  metabolically  well
characterised patients with NasH, and (ii) to identify
potential histological or biochemical parameters corre-
lating with individual breath test outcome.  
METHoDs
This cross-sectional study was carried out according to
Good Clinical Practice and the Declaration of Helsin-
ki.  Written  informed  consent  was  obtained  from  all
participants and the local Ethics Committee approved
the  protocol.  118  patients  with  suspected  non-alco-
holic fatty liver (Nafl) underwent histological exami-
nation of the liver after exclusion of other causes of
steatotic liver disease, such as viral hepatitis B or C vi-
ral  infection,  autoimmune  or  inherited  liver  disease
and toxic hepatitis (alcohol or drug induced). 18 lean
healthy individuals without hepatic steatosis (assessed
by  ultrasound)  and  normal  liver  laboratory  values
served as controls. Detailed characteristics of patients
and controls are given in Table 1. 
lIvER BIoPsy
The indication for performing a liver biopsy was based
purely on clinical reasons. liver tissue samples were
obtained by laparoscopic or ultrasound guided percu-
taneous needle biopsy within four weeks before study
entry, and evaluated according to the NasH scoring
system for steatosis, lobular inflammation, liver cell in-
jury, and fibrosis [19]. The NasH activity score (Nas)
was calculated by adding individual scores of steatosis,
lobular inflammation and ballooning, and ranked from
3-8.  Patients  were  subdivided  into  four  histological
groups: simple steatosis (Nas <3), borderline diagno-
sis (Nas 3-4), definite NasH (Nas 5-8), and NasH
cirrhosis. 
13C-METHIoNINE BREaTH TEsT (MeBT)
The  detailed  test  procedure  is  described  elsewhere
[13].  Briefly,  each  patient  received  2  mg/kg  body
weight  (methyl-13C)-labelled  methionine  (99%  atom
isotopic  enrichment,  Cambridge  Isotope,  andover,
Ma, usa) dissolved in 100 ml water. Breath samples
were obtained before substrate administration and at
10 minute intervals for 90 minutes. The 13C/12C iso-
tope ratio of the breath samples was analysed by non-
dispersive  isotope  selective  infrared  spectroscopy
(IRIs, Wagner analysen Technik, Bremen, Germany).
Primary results were expressed as the delta (ʴ) 13C/12C
isotope  ratio  over  baseline  (DoB).  To  measure  the
proportion of the metabolized substrate, the results
were expressed as percentage dose of  13C recovered
(PDR) over time for each time interval and cumulative
PDR (cPDR1.5h) after 90 min test time. 
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Table  1.  Baseline data and histological findings of 118 patients with histologically proven non-alcoholic fatty liver disease
(NaflD) and 18 lean controls. Data is presented as mean (sD).
Variable Lean  Simple  Borderline  Definite  NASH 
Controls Steatosis NASH NASH Cirrhosis
n = 18 n = 11 n = 47 n = 53 n = 7
Gender
Male, n  11 7 31 36 5
Female, n  74 16 17 2
Age, yr 44.0 (10) 51.0 (12) 50.5 (12) 49.5 (12) 59.0 (6)
BMI, kg/m2 24.4 (2.3) 24.6 (4.6) 27.4 (7.2)  30.3 (6.3) a 31.1 (4.6) a
Serum ALT, U/l 26 (8) 41 (12) 67 (40) a 94 (64) aa 64 (30) a
Cholesterol, mg/dl 172 (12) 243 (39) 235 (47) 216 (49) 189 (48)
Triglycerides, mg/dl 136 (17) 142 (75) 239 (1172) 211 (127)  185 (118)
Impaired glucose tolerance, n  00 15 21 2
Diabetes mellitus Type 2, n 02953
Fibrosis score, n
F 0 -9 11 2-
F 1 -1 29 28 -
F 2 -13 10 -
F 3 -04 13 -
ap<0.01 vs. simple steatosis and lean controls by Dunn’s post hoc test
Abbreviations: alT: alanine amino-transferase; BMI: body mass index; n: number of patients
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Biochemical evaluations included alanine aminotrans-
ferase  (alT),  total  cholesterol,  triglycerides,  and  an
oral glucose tolerance test (oGTT). Impaired or dia-
betic glucose tolerance was defined by the criteria of
the american Diabetes association. 
sTaTIsTICs
statistical analysis was firstly carried out as a descrip-
tive evaluation of cPDR1.5h (%) and clinical charac-
teristics of the patients. all data is presented as mean
ﾱ sD, unless otherwise specified. Differences in he-
patic mitochondrial function, as assessed by MeBT, of
different histological groups were tested by Kruskal-
Wallis aNova and Dunn’s post hoc tests. The rela-
tionship between categorical variables of liver histol-
ogy (NasH activity and fibrosis) and breath test out-
come was analysed by correlation analyses. The diag-
nostic  performance  of  cPDR1.5h to  detect  different
histological features was assessed by using receiver op-
erating characteristic (RoC) curves, and the area under
the RoC curve (auRoC) was used as a parameter of
accuracy. optimal cut-off values for MeBT were cho-
sen  to  obtain  suitable  sensitivity  and  specificity  for
clinical decision making. To define the relationship be-
tween MeBT results as expressed by cPDR1.5h and a set
of surrogate observations of the patient group, a mul-
tiple linear regression model using the procedure for
general linear models with cPDR1.5h as the dependent
variable and a set of explanatory variables (BMI, alT,
cholesterol, triglycerides, and diabetic predisposition)
was applied. In this model, all covariates have been in-
cluded based on an a priori decision guided by scien-
tific  knowledge  and  biologic  plausibility.  The  results
were regarded as significant when the error probability
was  less  than  0.05.  statistical  analysis  and  graphics
were  carried  out  by  commercial  software  programs
(Graph PaD Prism, version 4.01, san Diego, Ca).
REsulTs
PaTIENT CHaRaCTERIsTICs aND HIsToPaTHoloGy
REsulTs
all measurements were completed without complica-
tions or adverse events. liver histology confirmed the
presence of NaflD in all cases. The size of biopsy
specimens ranged from 18 to 32 mm and was consid-
ered adequate for the evaluation with the scoring sys-
tems employed by the pathologist. The major clinical,
biochemical and histological parameters of the partici-
pants included in the analysis are listed in Table 1. 
11 patients presented with simple steatosis, 47 cases
were  diagnosed  as  borderline  and  53  as  definite
NasH. The majority of patients (n = 81) presented
with no or mild fibrosis (f0-1), and only 7 patients
had complete cirrhotic conversion. Impaired glucose
tolerance (IGT) or type-2 diabetes was diagnosed in
49% of patients with predominance within the “bor-
derline” and NasH group. alT and BMI were signifi-
cantly  higher  in  patients  with  definite  or  borderline
NasH and NasH cirrhosis compared to individuals
with simple steatosis or lean controls (Table 1).
RElaTIoNsHIP BETWEEN BREaTH TEsT ouTCoME aND
DIffERENT HIsToloGICal GRouPs
Cumulative  13C-Exhalation  (  cPDR1.5h)  ranged  from
0.2 to 6.9% and was lower in patients with definite
NasH (3.24 ﾱ 1.12%) and NasH cirrhosis (1.32 ﾱ
0.94%) compared to individuals with simple steatosis
(6.36 ﾱ 0.56%) or borderline diagnosis (4.80 ﾱ 0.88%;
each p<0.001). lean controls ( cPDR1.5h: 6.15 ﾱ 1.2%)
and  patients  with  steatosis  or  borderline  diagnosis
could not be separated by MeBT, as illustrated by box
plot analyses (fig. 1).
To further explore the influence of fibrosis on he-
patic  methionine  metabolism,  additional  analyses  in
subgroups  of  patients  with  minimal  (f0-1)  and  ad-
vanced (f2-3) fibrosis stages were performed (fig. 2).
advanced fibrosis (f2-3) was associated with a signifi-
cant decline in  13C-exhalation both in the borderline
and NasH subgroup ( cPDR1.5h: 4.99 ﾱ 0.71% (f0-1)
vs. 2.88 ﾱ 0.78% (f2-3) in borderline NasH, and 3.82
ﾱ 0.87% (f0-1) vs. 2.50 ﾱ 0.95% (f2-3) in definite
NasH; p<0.001 and p<0.05, respectively). 
In  patients  with  mild  fibrosis,  the  difference  in
cPDR1.5h between borderline and definite NasH re-
mained significant ( cPDR1.5h: 4.99 ﾱ 0.71% vs. 3.82 ﾱ
0.87%; p<0.001), but in patients with advanced fibro-
sis, it was not possible to discriminate between border-
line and definite NasH or cirrhosis (2.88 ﾱ 0.78% vs.
2.50 ﾱ 0.95% vs. 1.32 ﾱ 0.94%; each p = n.s.) (fig. 2).
Correlation  analyses  confirmed  the  synergistic  nega-
tive effect of NasH activity and fibrosis on individual
breath test outcome (r = -0.62 for Nas and r = -0.77
for fibrosis stage; each p<0.001). NasH activity and
fibrosis were correlated (r = 0.36, p<0.001). 
The  relationship  between  histological  parameters,
selected biochemical variables (Chol, Trig, alT, and
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Fig.  1. Cumulative  13C-exhalation  after  1.5  h  test  time
(cPDR1.5h) in 118 patients with non-alcoholic fatty liver dis-
ease (Nafl) according to different histological stages (simple
steatosis,  borderline  diagnosis,  definite  NasH,  and  NasH
cirrhosis) and 18 lean controls. 
p<0.001  for  definite  NasH  and  NasH  cirrhosis  vs.  lean
controls,  simple  steatosis  and  borderline  diagnosis  by
Kruskal-Wallis ANOVA and Dunn’s post hoc tests.
4) Banasch_Umbruchvorlage  03.06.11  17:18  Seite 260diabetic predisposition) and breath test outcome was
further studied by multivariate analysis (Table 2). The
majority of variance (71%) could be attributed to his-
tological  parameters.  Cholesterol  was  the  only  bio-
chemical variable with a significant and positive associ-
ation with cPDR1.5h (r = 0.39, p<0.001) but could ex-
plain only 3.3% of variance in the entire model. 
RECEIvER-oPERaTING CHaRaCTERIsTIC (RoC) CuRvE
aNalysIs of MeBT PaRaMETERs
RoC curves of cumulative  13C-excretion ( cPDR1.5h)
were plotted to describe the diagnostic performance
of MeBT for the discrimination between patients with
definite NasH and those with only borderline diagno-
sis or simple steatosis (fig. 3a). The area under the
RoC curve (auRoC) was 0.87 for all fibrosis stages
and 0.83 for patients with only mild fibrosis (f0-1). 
a cPDR1.5h of <4.20% was chosen as an acceptable
cut-off  value  to  separate  patients  with  NasH  from
non-NasH in the total cohort (sensitivity: 81%; speci-
ficity: 76%). In the subgroup of low fibrosis (f0-1),
the optimal cut-off value increased to 4.6%, but the
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Fig.  2. Cumulative  13C-exhalation  after  1.5  h  test  time
(cPDR1.5h) in 99 patients with borderline diagnosis or definite
NasH stratified for the presence of advanced (f2-3) fibrosis
and 7 patients with complete cirrhotic conversion.
p<0.001 for f0-1 vs. f2-3 in each group and for f0-1 vs. cir-
rhosis; 
p<0.05 for f0-1 with borderline diagnosis vs. f0-1 with defi-
nite NasH
p = n.s. for f2-3 vs. cirrhosis by Kruskal-Wallis ANOVA
and Dunn’s post hoc tests.
Table 2. Multiple regression analysis of the relationship between breath test outcome (cPDR1.5h) and histological and biochemical
parameters.
Regression  Standardized  Standard  p-Value
coefficient regression error
coefficient
Intercept 6.219 - 0.622 <0.001
NASH activity score -0.449 -0.448 0.054 <0.001
Stage of fibrosis -0.732 -0511 0.075 <0.001
BMI -0.023 -0.074 0.016 0.156
Cholesterol 0.006 0.180 0.002 <0.001
Triglycerides 0.000 -0.031 0.001 0.535
ALT -0.001 -0.025 0.002 0.622
Diabetes -0.087 -0.041 0.108 0.420
Corrected R2 = 0.76 for the entire model
Abbreviations: alT: alanine aminotransferase; BMI: body mass index.
Fig. 3. RoC curves for 13C-methionine breath test outcome
parameter cumulative percentage recovery after 90 min test time
( cPDR1.5h) in patients with non-alcoholic fatty liver (Nafl).
a: for differentiation of non-NasH (steatosis and borderline-
diagnosis) from NasH in the total cohort (solid line) and a
subgroup  of  patients  (n  =  92)  with  mild  (f0-1)  fibrosis
(dashed line). B: for differentiation of non-significant (f0-1)
from advanced (f2-3) fibrosis in 99 patients with borderline
diagnosis or definite NasH. 
B
A
4) Banasch_Umbruchvorlage  03.06.11  17:18  Seite 261overall  test  performance  declined  slightly  (sensitivity
77%; specificity 73%). 
In a similar approach, the accuracy of MeBT to dif-
ferentiate advanced (f2-3) from mild (f0-1) fibrosis
within  the  NaflD  cohort  was  estimated  (fig.  3b).
The area under the curve (auRoC) was 0.90. a cPDR
value <3.65% was calculated to be the cut-off value
with an optimal balance between sensitivity and speci-
ficity.
DIsCussIoN
In the present study, we demonstrated that non-alco-
holic  steatohepatitis  is  associated  with  a  substantial
impairment of hepatic mitochondrial function, which
can be measured in vivo by a simple non-invasive 13C-
breath test. We found a significant and independent
inverse correlation of  13C-methionine excretion with
NasH activity, measured by the NasH scoring system
and fibrosis stage. The rising prevalence of NaflD
which  shows  a  progressive  disease  in  approximately
10-20% of patients, and the known disadvantages of
liver  biopsy  (invasiveness,  potentially  fatal  complica-
tions and sampling error) illustrate the need for new
non-invasive diagnostic techniques. Ideally, these diag-
nostics  should  discriminate  simple  steatosis  from
steatohepatitis, and differentiate initial and advantage
stages of fibrosis. Most promising progress has been
made  in  developing  non-invasive  techniques  for  the
quantification of fibrosis and inflammation. yoneda et
al. evaluated the performance of transient elastogra-
phy in 97 NaflD patients and reported a 88% sensi-
tivity and 74% specificity for diagnosis of septal fibro-
sis (f≥2) corresponding with an area under the receiv-
ing operating curve (auRoC) of 0.87 [20]. More re-
cently, cytokeratin 18 (Ck-18) has been introduced as
a novel, promising serum parameter for non-invasive
diagnosis of NasH. Ck-18 reflects the amount of liv-
er  cell  apoptosis,  which  is  characteristic  for  disease
progression  from  simple  steatosis  to  steatohepatitis.
The  accuracy  (auRoC)  of  Ck-18  to  differentiate
Nafl from NasH ranges from 0.83 to 0.88, depend-
ing on the study setting [21-23]. 
analogous  to  liver  cell  apoptosis,  mitochondrial
dysfunction  is  a  key  characteristic  of  non-alcoholic
fatty liver that promotes the development of steatosis
and  further  progression  to  steatohepatitis:  inherited
defects of beta oxidation and pharmacological inhibi-
tion of mitochondrial respiratory chain activity in ro-
dents are associated with steatohepatitis that is histo-
logically indistinguishable from NaflD in humans [6,
7].  Many  genes  encoding  mitochondrial  proteins  in
skeletal muscle and fat are negatively correlated with
body mass [8, 24, 25] NaflD is commonly associated
with obesity and insulin resistance; both conditions are
characterized by decreased oxygen consumption, aTP
production, and reduced content of respiratory pro-
teins  in  the  fat,  muscle  and  liver  [8].  although  the
metabolic pathway of methionine within hepatocytes
does not involve enzymes of beta oxidation or respira-
tory chain complex, it seems to be very sensitive to
conditions  of  mitochondrial  stress,  as  we  could
demonstrate in previous studies of HIv/HCv and an-
tiviral  drug  related  mitochondrial  toxicity.[15,  26]
spahr et al. used this technique first for the examina-
tion of selected patients with severe (>40%) steatosis
and reported a significant decay (-49% compared to
healthy controls) of mitochondrial methionine decar-
boxylation in this patient group [12]. To our knowl-
edge, our study is the first evaluating the diagnostic
power of a new non-invasive metabolic function test
in a large cohort of metabolically well characterized
patients. We could demonstrate as a major finding that
individual  13C-methionine breath test performance is
associated with histological parameters that are charac-
teristic for non-alcoholic steatohepatitis. Including all
stages of fibrosis, the accuracy of the 13C-methionine
breath  test,  to  separate  patients  with  steatohepatitis
from patients with a pure steatosis, seems to be com-
parable to the diagnostic performance of serum Ck-
18 measurements. These promising results, however,
have to be interpreted cautiously since further analyses
correcting  for  fibrosis  showed  a  decline  in  accuracy
for this relevant diagnostic question (auRoC 83%).
Whether  this  reduction  in  diagnostic  accuracy  was
caused by the weak, but positive, correlation of key
histopathological features, NasH activity and fibrosis
(r = 0.36, p<0.001), or by the relatively small number
of patients remains unclear and should be addressed
in further studies. In an analogous fashion, the validity
of  the  MeBT  as  a  non-invasive  marker  of  hepatic 
fibrosis cannot be conclusively judged from this study,
given the fact that the limited number of patients with
advanced fibrosis also had higher grades of NasH ac-
tivity, a factor that may independently, but concordant-
ly, influence the outcomes of the breath test. Thus, in
order to gain a better understanding regarding sensi-
tivity and specificity of this non-invasive technique, it
would be necessary to examine larger groups of pa-
tients at well defined stages of NasH activity and fi-
brosis.  Ideally,  such  studies  should  also  implement
other non-invasive markers such as Ck-18 for a better
group stratification, which was not available during the
time this study was conducted. 
furthermore,  the  pathophysiological  basis  of  the
13C-methionine breath test has to be clarified more in
detail. at this point, the underlying molecular mecha-
nism that determines the poor breath test results in
patients with Nafl, as well as in other mitochondria-
effecting liver diseases such as hepatitis C or HIv, are
largely unclear. owing to the pilot nature of this study,
the small amounts of liver tissue available from the
patients has been primarily used for histological exam-
inations. Nevertheless, more detailed analyses of mito-
chondria-specific structures and functions are certainly
warranted  in  order  to  establish  the  13C-methionine
breath test as a routine instrument in clinical practice.
along  these  lines,  a  recently  published  study  by
Mawatari et al. examined mitochondrial beta-oxidation
in patients with NasH using a non-invasive  13C-oc-
tanoate breath test [27]. In this study, no significant
differences  in  breath  test  performance  between  the
study groups (Nafl, NasH) were found, suggesting
that the beta-oxidation is not generally impaired in pa-
tients with non-alcoholic steatohepatitis. 
With respect to the limitations stated above, what
could the potential applications and advantages for the
MeBT in clinical practice be? We propose the two fol-
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NaflD,  a  cumulative  13C-exhalation  (cPDR1.5h)
<4.2% indicates definite NasH, and should be inter-
preted in favour of performing a liver biopsy. In those
patients with a histologically confirmed diagnosis, the
MeBT  might  a  useful  tool  to  prospectively  monitor
disease progression or potential benefits due to thera-
peutic  interventions,  as  could  be  shown  recently  by
our group [16, 27]. The majority of NasH patients
present at early stages of fibrosis at the time of prima-
ry diagnosis. These patients are typically not at risk of
rapid  fibrosis  progression,  and  might  experience  a
greater  benefit  from  non-invasive  diagnostic  proce-
dures which accurately measure the extent of NasH
activity, rather than liver fibrosis.
Given the lack of specificity for inflammatory and
fibrotic changes, and in consideration of the impact of
NaflD-independent factors (alcohol, viral infections,
etc.), it seems unlikely that the 13C-methionine breath
test - as with other non-invasive markers - could com-
pletely replace liver biopsies for diagnosing and stag-
ing  of  NasH.  Nevertheless,  the  13C-methionine
breath test could serve as a valuable supporting diag-
nostic instrument in NaflD and NasH, which may
help  to  individualize  diagnostic  procedures,  and  to
minimize the necessity of liver biopsies in this chronic
disease.
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